S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Ultragenyx Pharmaceutical Stock Forecast, Price & News

+0.58 (+0.97%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
653,293 shs
Average Volume
507,587 shs
Market Capitalization
$4.24 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock Forecast (MarketRank)

Overall MarketRank

2.28 out of 5 stars

Medical Sector

294th out of 1,417 stocks

Pharmaceutical Preparations Industry

119th out of 675 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Ultragenyx Pharmaceutical logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

RARE Stock News Headlines

Expert Ratings for Ultragenyx Pharmaceutical
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
$-454.02 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$351.41 million
Book Value
$13.53 per share


Free Float
Market Cap
$4.24 billion

Ultragenyx Pharmaceutical Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2022?

12 equities research analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their RARE stock forecasts range from $73.00 to $162.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $111.29 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical
or view top-rated stocks among Wall Street analysts.

How has Ultragenyx Pharmaceutical's stock price performed in 2022?

Ultragenyx Pharmaceutical's stock was trading at $84.09 at the beginning of the year. Since then, RARE shares have decreased by 28.0% and is now trading at $60.57.
View the best growth stocks for 2022 here

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for Ultragenyx Pharmaceutical

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.76) by $0.43. The biopharmaceutical company earned $79.94 million during the quarter, compared to the consensus estimate of $84.25 million. Ultragenyx Pharmaceutical had a negative net margin of 141.65% and a negative trailing twelve-month return on equity of 49.18%. Ultragenyx Pharmaceutical's quarterly revenue was down 19.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.03) EPS.
View Ultragenyx Pharmaceutical's earnings history

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.53%), Federated Hermes Inc. (5.70%), BlackRock Inc. (4.96%), Wellington Management Group LLP (4.82%), Capital International Investors (4.78%) and Clearbridge Investments LLC (4.10%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Invesco Ltd., Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Capital Group International Inc. CA , BlackRock Inc., Capital International Ltd. CA, and Citigroup Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last two years include Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Rock Springs Capital Management LP, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, International Biotechnology Trust PLC, Verition Fund Management LLC, and Verition Fund Management LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $60.57.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $4.24 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454.02 million in net income (profit) each year or ($6.87) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical employs 1,119 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.